News

A U.S. government-backed initiative against drug-resistant bacteria has awarded Antabio $2.8 million to continue developing treatments for Pseudomonas, the most common infection in cystic fibrosis (CF). The grant came from a public-private partnership known as CARB-X, which stands for Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator. CARB-X, formed in July 2016,…

Vertex Pharmaceuticals is continuing to develop treatments for all people with cystic fibrosis (CF), with clinical trials exploring combinations of its potentiator and corrector therapies. At the same time, efforts to expand the use of already-approved treatments are ongoing. In addition, the company recently completed the purchase of Concert’s…

Electromed recently launched a SmartVest Connect wireless technology to complement the SmartVest SQL, a technology that allows doctors and patients with certain lung diseases, such as cystic fibrosis or bronchiectasis, to have access to treatment information and collaborate in care decisions. The device developed by Electromed, the SmartVest Airway Clearance…

Three triple-combination treatments from Vertex Pharmaceuticals showed promising results in Phase 1 and Phase 2 clinical trials in cystic fibrosis (CF) patients with one F508del mutation and one so-called minimal function mutation (F508del/Min) in the CFTR gene, the defective gene that causes CF. Vertex announced that these are the first data to demonstrate…